公告日期：2024-09-30

Huadong Medicine Co., Ltd.

Semi-Annual Report 2024

August 16, 2024

Section I. Important Declaration, Contents and Definitions

The Board of Directors, Board of Supervisors, directors, supervisors and
senior managers of Huadong Medicine Co., Ltd. (hereinafter referred to as the
“Company”)herebyguaranteethattheinformationpresentedinthis semi-annual
report is authentic, accurate and complete, and free of any false records,
misleading statements or material omissions, and shall undertake individual and
joint legal liabilities.

Lv Liang, the Company’s legal representative and the officer in charge of
accounting, and Qiu Renbo, head of accounting department (accounting
supervisor) hereby declare and guarantee that the financial statements in this
semi-annual report are authentic, accurate and complete.

All directors have attended the Board of Directors meeting to review this
semi-annual report.

The future plans, development strategies and other forward-looking
statements in this semi-annual report shall not be considered as substantial
commitment of the Company to investors. Investors and related parties should be
fully aware of the risks, and understand the differences between plans, forecasts
and commitments.

The risks the Company faces in operation include industry policy and
product price reduction risk, new drug R&D risk, investment and M&Arisk and
exchange rate fluctuation risk. For details, please refer to “X. Risks and
Countermeasures” in “Section III. Management’s Discussion and Analysis”.

Therefore, investors are kindly reminded to pay attention to possible investment
risks.

The dividend distribution scheme approved at the meeting of the Board of
Directors is asfollows:Onthebasisof1,754,262,548sharesthatareobtainedafter
removing 65,000 restricted shares that have not been repurchased and canceled
from the total share capital of 1,754,327,548 shares of the Company, 3.50 yuan
(before tax) of cash dividends per ten common……
[点击查看PDF原文]

提示：本网不保证其真实性和客观性，一切有关该股的有效信息，以交易所的公告为准，敬请投资者注意风险。